c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. by Schroeter, C. A. et al.
Br. J. Cancer (1992), 66, 728-734 © Macmillan Press Ltd., 1992
c-erbB-2 positive breast tumours behave more aggressively in the first
years after diagnosis
C.A. Schroeter', C.R. De Potter2, K. Rathsmann3, R.G.J. Willighagen4 & J.C. Greepl
'Department ofSurgery, University Hospital, Maastricht, The Netherlands; 2N. Goormaghtigh Institute ofPathology, University
Hospital, Gent, Belgium; 3Department ofMedical Statistics, Rheinisch Westfaelische Technische Hochschule, Aachen, Germany;
4Department ofPathology, University Hospital, Maastricht, The Netherlands.
Summary In a retrospective study the expression of the c-erbB-2 oncogene was determined immunohisto-
chemically in 276 breast cancer samples from 253 patients with the antibody 21N. The follow-up period was
between 7 and 12 years. This study showed a trend for an inverse relationship between c-erbB-2 positive
tumours and estrogen receptors (ER). A correlation was assessed between c-erbB-2 positive tumours and
histological grade, liver metastases as first site of metastases, disease free survival time (DFS) in the second
and third year after diagnosis and overall survival time (OST) in the third and fourth year after diagnosis. A
trend was seen between c-erbB-2 positive tumours and tumour size. No correlation was found between
c-erbB-2 positive tumours and age at diagnosis. The method of operation and lymph node involvement. From
this study we conclude that there is a significant difference in prognosis the first years after diagnosis, but this
difference seems to vanish in a longer follow-up period of 12 years. This provides us with an explanation for
the discrepancies in literature concerning c-erbB-2 expression and prognosis in breast cancer. Some investi-
gators did not show differences in prognosis between positive and negative cases after a long follow-up period
whereas investigations with a short term follow-up period up to 2-3 years have indeed established a more
aggressive behaviour of c-erbB-2 overexpressionary tumours.
The c-erbB-2 or HER-2/neu oncogene encodes a transmemb-
raneous glycoprotein with tyrosine kinase activity. The gene
was first described in rat neuroglioblastoma induced by treat-
ment with a carcinogen (Schechter et al., 1984). C-erbB-2 or
neu has important sequence homology with the epidermal
growth factor receptor. (Schechter et al., 1984; Bargmann et
al., 1986). Amplification and overexpression were found
especially in breast cancer (Yakota et al., 1986) and gastric
carcinomas (Falck & Gullick, 1989).
Increased copy numbers in breast carcinomas were related
to bad prognosis by some authors (Cline et al., 1987; Slamon
et al., 1987; Varley et al., 1987; Slamon et al., 1989). These
results were refuted by others (Ali et al., 1988; Zhou et al.,
1989). Gene amplification of c-erbB-2 correlated with lymph-
node involvement (Slamon et al., 1987; Zhou et al., 1987;
Slamon et al., 1989; Guerin et al., 1989; Tavassoli et al.,
1989), histological grade (Berger et al., 1988; Tavassoli et al.,
1989; Tsuda et al., 1989, Paik et al., 1990), negative ER-
content (Cline et al., 1987; Guerin et al., 1989; Zeillinger et
al., 1989; Heintz et al., 1990), early recurrence (Zhou et al.,
1987; Cline et al., 1987; Varley et al., 1987), short overall
survival time (cline et al., 1987; Slamon et al., 1987; Varley et
al., 1987; Slamon et al., 1989; Paik et al., 1990) and increased
mitotic activity (Heintz et al., 1990; Ramachandra et al.,
1990). All of these factors are considered to be bad prognos-
tic indicators. According to other authors there was no cor-
relation with tumour size (Gutman et al., 1989; Seshadri et
al., 1989) and age at diagnosis (Zhou et al., 1987; Seshadri et
al., 1989).
Studies were also carried out on the protein of c-erbB-2 by
the immunoperoxidase method on primary cancers and meta-
stases. Correlations were found between membrane staining
tumours and patho-histological findings such as tumour size
(van de Vijver et al., 1988), negative ER-content (De Potter
et al., 1989a; Thor et al., 1989; Wright et al., 1989a; Kom-
moss et al., 1990; De Potter et al., 1990), lymph node
involvement (Berger et al., 1988; Thor et al., 1989), histo-
logical grade (berger et al., 1988; Barnes et al., 1988; Wright
et al., 1989a) and survival time (Thor et al., 1989; Wright et
al., 1989a).
Furthermore a trend towards worse prognosis was found
by others (Barnes et al., 1988; Thor et al., 1989; Walker et
al., 1989; Paik et al., 1990; De Potter et al., 1990). This
immunohistochemical study with a clinical follow-up of up to
12 years was carried out to investigate a putative relationship
between the c-erbB-2 oncogene and factors for prognosis.
The aim of this study was to establish an explanation for the
discrepancies in prognosis in the literature in a large number
of patients.
Materials and methods
Patients and treatment
Tumour specimens were investigated from 251 female and
two male patients with primary breast cancer from the De-
Wever-Ziekenhuis in Heerlen, the Netherlands. Patients were
chosen by haphazard from 1978-1982. Tumour samples were
embedded in buffered formalin and could be used for the
indirect immunoperoxidase method. Haematoxylin slides of
the primary tumours and the metastases were reviewed.
Clinical and pathohistological data as well as patient follow-
ups were assessed. Table IA shows the number of patients in
each category of prognostic variables.
The patients were treated surgically depending on the
clinical status at the time of diagnosis. For patients with
minimal disease, TI, or tumours of <2 cm, a breast-saving
quadrantectomy or radical mastectomy was performed. For
patients with intermediate disease, T2, tumours of 2-5 cm,
not fixed on the skin or chest wall, mastectomy and axillary
clearance were carried out. In cases of breast-saving opera-
tions with negative lymph nodes the regional lymph nodes
were treated with radiotherapy. In patients with positive
lymph nodes adjuvant chemotherapy, six cycles with cyclo-
phosphamide, methotrexate and flurouracil (CMF) was
administered instead of radiotherapy. After the operation,
patients with T2 or T3 tumours and negative lymph nodes,
but localisation of the tumour in the upper or lower medial
quadrant or in the centre, received radiotherapy. If the lymph
nodes were involved adjuvant chemotherapy was added.
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Table IA Prognostic data of patients with invasive ductular car-
cinomas
Data Total Med-Std. Dev.
Age 59.07 12.89
20-50 59
51-65 106
66-90 67
ER
neg. 76
pos. 119
Hist. grade
I 13
II 164
III 41
Lymph nodes
None inv. 102
1-3 58
>3 52
c-erbB-2
Pos. 35
Neg. 197
Tumour size 3.22 1.74
<5cm 80
>5cm 132
Table lB Primary and adjuvant treatments in invasive ductal car-
cinoma patients
Data Total
Method of operation 232
Mastectomy with ax. clearance 138
Simple mastectomy 44
Quadrantectomy 43
Biopsy 3
Radiotherapy 68
Radio- and chemotherapy 7
Radiotherapy and Tamoxifen 9
Chemohormonal therapy 32
Adjuvant chemotherapy 46
Adjuvant Tamoxifen 31
Ovariectomy 1
Paget's disease of the nipple was treated with mastectomy
and axillary clearance because of its central position. In
patients with T4 tumours a biopsy was taken from the
primary tumour to determine the ER-status; courses of
chemotherapy were given immediately after diagnosis. Simple
mastectomy, radiotherapy or a combination of both fol-
lowed. From 1980 onward all patients with tumour stage
1-4, postmenopausal and positive ER were given tamoxifen
as hormonal treatment.
The general follow-up for breast cancer patients after 1982
was based on clinical status mammography, chest X-ray and
laboratory diagnosis. Bone metastases were diagnosed in the
skeleton by scintigram, bronchial metastases by chest X-ray
and cytology and liver metastases by ultrasound and
laboratory investigations.
Local recurrences were pathohistologically confirmed and
were treated surgically or with radiotherapy or both or with
hormonal adjuvants regardless of the stage of the tumour.
To patients with liver metastases six cycles of CMF were
administered. Bone metastases were radiated. If ER was
positive, these patients were given Tamoxifen. Lung metas-
tases were treated with six cycles of CMF and with Tamox-
ifen if ER was positive. Pleural metastases and pleural
effusion were treated with an intra-pleural administration of
neomycin. Solitary brain metastases were enucleated depend-
ing on the localisation. Table IB gives the number of patients
with the method of primary and adjuvant treatment. The
follow-up period varied between 7 and 12 years, depending
on the age of the patients, if they were older than 80 the
patients were in part reviewed by their GPs. Some of the
patients were not available because of lost follow-up.
Indirect immunoperoxidase method
Five micro m sections from blocks of breast cancer fixed in
4% formalin (buffered with phosphate) and embedded in
paraffin were dewaxed, rehydrated and washed in phosphate
buffered saline (PBS). The peroxidase-anti-peroxidase tech-
nique was applied as follows:
(1) immersion of deparaffinised sections in methanol con-
taining 0.03% hydrogen peroxidase for 20 min to block
the endogenous peroxidase activities and incubation with
5% bovine serum albumin for 30min.
(2) Incubation with rabbit polyclonal anti-c-erbB-2 antibody
21N diluted at 1/200 for 60min (Gullick, ICRF, Ham-
mersmith Hospital, London); and rinsed three times with
P.B.S. and 1% bovine serum albumin (B.S.A) for
5 min.
(3) Biotinilated swine-anti-rabbit immunoglobulin diluted at
1/80 for 30 min (Dako-patts, Glostrup - Denmark); and
rinsed three times with B.S.A. for 5 min.
(4) Avidin-biotin peroxidase complex for 30 min (Dako-
patts, Glostrup - Denmark).
(5) The peroxidase reaction was developed using 3-3 dia-
minobenzidine (Sigma, St Louis - USA) with 0.01%
hydrogen peroxide for 10 min followed by washing in tap
water. The nuclei were counterstained with haematox-
ylin. All sections were dehydrated and mounted. Control
specimens were prepared by omitting the primary anti-
body. One slide identified as being positive for c-erbB-2
was taken as positive control.
Antibody
21N as a polyclonal antibody was raised against a synthetic
peptide derived from the c-erbB-2 oncogene product contain-
ing the amino acid residues 1243-1255 of the c-terminus of
the protein of c-erbB-2 (Gullick et al., 1987).
Oestrogen receptor content
The ER-content was determined in 226 tumour specimens by
the dextran coated charcoal technique. The hormonal con-
tents were expressed as fmolmg-' protein. Values of more
than 10fmolmg-' protein were considered as positive,
whereas values lower than 10 fmolmg' protein as ER
negative.
Pathological assessment
The slides were reexamined for correct grading and categoris-
ing. The size of the tumour and the number of lymph nodes
were determined. The breast cancers were divided pathohis-
tologically into 239 invasive ductular carcinomas, 16 intra-
ductular carcinomas (DCIS), 21 invasive lobular carcinomas
and two cases of Paget's disease of the nipple. The invasive
ductular carcinomas were again divided into stage 1, 2 and 3
according to histological grade.
All primary and secondary tumour specimens were exam-
ined by two independent observers. The immunohistochem-
ical staining was scored as positive if there was membrane
staining. Cytoplasmic staining was not considered specific for
the c-erbB-2 protein since only membrane staining was con-
sidered specific as previously shown (De Potter et al.,
1989b).
Statistical analysis
Clinical and pathohistological factors in relation to c-erbB-2
over-expression were assessed by Fisher's exact test (Hartung,
1985). Age at diagnosis was calculated with the Wilcoxon
Rank Sum test (Hartung, 1985).
In a multivariate analysis, using an accelerated life model
(Cox & Oakes, 1984), the relation between DFS and OST
and the following prognostic factors as: C-erbB-2 over-
expression, histology, lymph node status, ER, method of
operation, age at diagnosis and tumour size were calcul-
ated.730 C.A. SCHROETER et al.
The actuarial curves for DFS and OST were calculated
with the Kaplan-Meier technique. The tumour size was the
strongest prognostic factor in the accelerated life model.
Adjusting for tumour size the probability of recurrence at
fixed time periods after 6, 12, 18, . . . 36 months, respectively
the probability of survival at fixed time periods after 6, 12,
18, . . . 36 months was assessed under consideration of the
c-erbB-2 over-expression with the Cockran-Mantel-Haenzel
test (Agresti, 1990). Neglecting all other clinical and patho-
histological factors DFS and OST were tested for the c-erbB-
2 over-expression with the Log Rank and Wilcoxon test. All
P-values are two sided.
Results
Tumours were only scored as positive if the membrane was
stained (Figure 1). A different cytoplasmic staining pattern
was observed in some normal cells and some tumour cells,
but was not considered specific for the c-erbB-2 protein. Each
tumour was assessed according to the following criteria:
(1)
(2)
(3)
Scoring of the membrane.
Assessment of different components within the tumour
(e.g. invasive duct./intraductular).
Comparison of the staining of primary tumours and
involved lymph nodes.
Normal breast tissue, if found, only showed granular cyto-
plasmic staining. Smooth muscle cells and the upper layers of
the epidermis tended to have cytoplasmic staining, which
again was not considered specific for the expression of the
protein of the c-erbB-2 oncogene.
For the statistical analysis only patients with invasive duc-
tular carcinomas were used. Thirty-five of 232 (15.1%)
patients with invasive ductular carcinomas showed membrane
staining tumours. The median age of the c-erbB-2 positive
patients was 57.8 and the median age of the negative patients
was 59.3.
A trend for an inverse correlation between membrane
staining tumours and ER content was seen (P = 0.078)
(Table II). A correlation between membrane staining
tumours and the histological grade was found (P = 0.003)
(Table II). None of the twenty-one invasive lobular car-
cinomas was positive for c-erbB-2. Three of the four intra-
ductular carcinomas were positive, one of these three also
had an an intralobular component, which was negative. An
invasive carcinoma grade 3 with an in situ component show-
ed membrane staining in the invasive as well as in the in situ
part. The two cases of Paget's disease of the nipple showed
membrane staining and the two underlying invasive grade 2
carcinomas. The Paget cells were of large size with large
nuclei and prominent nucleoli.
Concerning the tumour size a trend was found between
c-erbB-2 tumours and a tumour size larger than 5 cm
(P = 0.055) (Table II). A correlation was seen between the
tumours which expressed the protein of c-erbB-2 and site of
first metastasis. The liver was the only tissue to have a
correlation with c-erbB-2 positive tumours (P<0.05) (Table
III). No correlation was found between the over-expression
of the c-erbB-2 oncogen and age at diagnosis (P = 0.66),
method of operation (P = 0.084) and axillary lymph-nodes
(P = 0.18) (Table II). There was some difference in the mem-
brane staining between primary tumours and their lymph
node metastases. In 3/7 (42.9%) of the lymph node metas-
tases the tumour cells showed a less marked membrane stain-
ing. The number of positive cells was also lower than in the
primary tumour.
There was a significant correlation between over-expression
Figure 1 Immunohistochemical staining with 21N. Invasive duct-cell carcinoma stained for the c-erbB-2 oncogene product with
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Table II c-erbB-2 membrane staining in relation to clinical and
pathological findings
Data c-erbB-2 pos. c-erbB-2 neg. Total P value
Hist. grade
I 0/13 13/13
II 20/164 144/164
III 13/41 28/41 218 0.003
Lymph nodes
None inv. 12/102 90/102
Pos. 21/110 89/110 212 0.185
ER
Neg. 17/76 59/76
Pos. 15/119 104/119 195 0.078
Tumour size
<5 cm 7/80 73/80
>5 cm 28/152 124/152 232 0.055
Method ofoperation
Mast.+ax. cl. 19/138 119/138
Mast. - ax. cl. 9/44 35/44
Quandrantectomy 5/43 38/43
Biopsy 2/3 1/3 232 0.084
Age at diag.
<50 7/59 52/59
>50 28/173 145/173 232 0.66
Table III Expression of c-erbB-2 in relation to site of first metas-
tases
Metastases c-erbB-2 pos. c-erbB-2 neg. P value
Bone 6 (24%) 23 (31.1%)
Liver 8 (32%) 9 (12.2%) <0.05
Brain 0 2 (2.7%)
Pleura 1 (4%) 4 (5.4%)
Lung 2 (8%) 7 (9.5%)
Local 5 (20%) 18 (24.3%)
Others 1 (4%) 3 (4.0%)
Lymph-nodes 2 (8%) 8 (10.8%)
25 (100%) 78 (100%)
of c-erbB-2 and a bad prognosis. A multivariate analysis was
performed to determine whether c-erbB-2 was an independent
prognostic factor for DFS and OST. Clinical and pathohisto-
logical factors were tested. Tumour size was the strongest
prognostic factor for both DFS (P = 0.0003) and OST (P =
0.0081). Another confounding factor for DFS was method of
operation (P = 0.009). For OST age at diagnosis was a con-
founding factor (P = 0.011). Lymph node status showed a
trend as confounding factor (P = 0.0499) (Table VA and B).
The difference in DFS, neglecting all other clinical and
pathohistological factors, was statistically significant with the
Log Rank test (P = 0.025) and with the Wilcoxon test
(P = 0.007). Most of the recurrences were seen in the first 3
years after diagnosis (Table IVA). After adjusting tumour
Table IVA c-erbB-2 positive and negativepatients at6monthsperiods
within DFS
Months c-erbB-2 pos. c-erbB-2 neg. P value
0 34 185 0.09
6 27 171 0.44
12 24 155 0.03
18 18 144 0.008
24 15 136 0.01
30 13 124 0.06
36 13 116 0.12
42 13 111 0.25
48 13 103 0.49
54 13 95 0.54
60 12 88 0.31
66 10 83 0.13
72 10 74
Table IVB c-erbB-2 positive and negative patients at 6 monthperiods
within OST
Months c-erbB-2 pos. c-erbB-2 neg. P value
0 34 187
6 32 184 0.25
12 30 169 0.75
18 26 162 0.58
24 22 159 0.07
30 20 152 0.09
36 17 143 0.05
42 15 138 0.02
48 15 126 0.12
54 15 125 0.14
60 14 123 0.08
66 14 120 0.23
72 14 96 0.75
size with the Cockran-Mantel-Haenzel test a correlation was
found between c-erbB-2 positive tumours and the probability
of recurrence after 18, 24 and 30 months (Table VA). A
trend was found between c-erbB-2 positive patients and OST
with the Wilcoxon test (P = 0.06). 61.8% ofc-erbB-2 positive
patients died within the first 4 years after diagnosis (Table
IVB). Taking tumour size into consideration a correlation
with the Cockran-Mantel-Haenzel test was found between
c-erbB-2 positive tumours and OST after 36 and 42 months
(Table VB). Both Tables VA and VB show the estimates and
the standard errors of the regression-coefficients in the
accelerated life model for DFS and OST. (Figures 2 and 3
show the actuarial curves for DFS and OST).
Discussion
In this retrospective study the expression of the c-erbB-2
protein was determined immunohistochemically in breast
cancer patients in relation to its clinical and pathohistological
features. Membrane staining with antibodies against the c-
erbB-2 protein is known to be related to DNA amplification
(Venter et al., 1987; Gusterson et al., 1988; Walker et al.,
1989) and is considered to be the only expression of the
c-erbB-2 oncogene, as cytoplasmic staining was shown not to
Table VA Estimates and its standard errors of the regression
coefficients in the acclerated lifemodel for DFS and the Pvalues for the
Chi-square test
Progn.-Factor Value Estimate StdErr P value
Intercept 2.938 0.783 0.0002
Age 0.002 0.005 0.6564
Tumour size -0.144 0.040 0.0003
c-erbB-2 0.2041
neg. 0.193 0.151
pos. 0 0
Hist. Grade 0.1394
1 --0.447 0.376
2 -0.570 0.288
3 -0.314 0.288
5 0 0
Lymph nodes 0.2521
non. inv. 0.262 0.161
1-3 0.131 0.158
>3 0 0
ER 0.9696
<10 fmol -0.005 0.124
>lOfmol 0 0
Method of 0.0009
operation
1 1.997 0.705
2 1.542 0.710
3 1.687 0.711
4 0 0
Methodofoperation: 1 mast. +ax.cl., 2 mast. - ax.cl.,3 quandrantec-
tomy, 4 biopsy.732 C.A. SCHROETER et al.
be related to c-erbB-2 expression (De Potter et al., 1989b).
We found positive membrane-staining in 15.1% of primary
breast cancers.
Table VB Estimates and its standard errors of the regression
coefficients in theacclerated lifemodel forOSTand the Pvalues forthe
Chi-square test
Progn.-Factor Value Estimate StdErr P value
Intercept 4.467 0.682 0.0001
Age -0.011 0.004 0.0110
Tumour size - 0.103 0.039 0.0081
c-erbB-2 0.8742
neg. 0.025 0.153
pos. 0 0
Hist. Grade 0.8446
1 -0.052 0.359
2 -0.181 0.262
3 -0.178 0.263
5 0 0
Lymph nodes 0.0499
non. inv. 0.363 0.148
1-3 0.214 0.146
>3 0 0
ER 0.9763
<10 fmol -0.004 0.121
>10 fmol 0 0
Method of 0.1472
operation
1 0.719 0.601
2 0.397 0.606
3 0.596 0.610
4 0 0
Methodofoperation: I mast.+ax.cl., 2mast. - ax.cl., 3 quandrantec-
tomy, 4 biopsy.
A trend for an inverse correlation was found between
c-erbB-2 positive tumours and the ER status. This result
confirms the studies done by De Potter et al., 1989a; Thor et
al., 1989; Wright et al., 1989a; Kommuss et al., 1990; De
Potter et al., 1990; O'Reilly et al., 1991.
It has been demonstrated that c-erbB-2 expression is under
hormonal regulation (Dati et al., 1990). c-erbB-2 expression
is not present in breast tissue in virgin mice and in the first 2
weeks of pregnancy when oestrogen and progesterone levels
are high and maximum proliferation activity is seen. Protein
expression of c-erbB-2 increases at the end of pregnancy and
at the beginning of the lactation period in mice, when pro-
liferation declines and differentiation begins. Oestrogens are a
controlling factor of the protein expression of c-erbB-2.
Under the influence of oestrogens, c-erbB-2 expression is
inhibited. This fact agrees with our findings that c-erbB-2
expression is found more frequently in ER-negative tumours.
The ER negative tumours are known to behave more aggres-
sively and to metastasise faster than ER positive tumours
(Oster, 1986). ER negative tumours, which are c-erbB-2
positive, have the tendency to respond less on hormonal
therapy (Wright et al., 1989b).
The OST in c-erbB-2 negative patients after recurrence is
longer, because most of these tumours are ER positive and
respond much better to hormonal treatment. Metastases of
ER positive tumours are found most of the time in bone,
lung, pleura and are not as aggressive as metastases in liver
or brain, which are often seen in ER negative and c-erbB-2
positive patients. This fact agrees with our finding, six out of
eight patients who were c-erbB-2 positive and had liver
metastases died within the first 2 years after diagnosis and
did not respond to any hormonal treatment.
The responsiveness ofc-erbB-2 positive tumours on chemo-
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Figure 3 OST in c-erbB-2 positive and negative patients at 6 month intervals.
therapy is debated (Gullick et al., 1991). The question is
raised whether these tumours are resistant on chemotherapy
(O'Reilly et al., 1991), what requires further studies to inves-
tigate this hypothesis. Furthermore a trend was seen between
membrane staining tumours and tumour size, confirming the
findings of van de Vijver et al., 1988. Another correlation
was found between over-expression of c-erbB-2 tumours and
histological grade. Berger et al., 1988; Barnes et al., 1988;
Wright et al., 1989a; Gullick et al., 1991; Lovekin et al., 1991
came to the same results.
From this study we conclude that c-erbB-2 membrane-
staining tumours spread, especially to the liver, which
confirms a previous prospective study with a short follow-up
period (De Potter et al., 1989b). The particular pattern of
metastasis to the liver could be explained with the production
of a factor in the liver which stimulates the growth and
spread of c-erbB-2 tumour cells. This factor may also be
present in foetal liver tissue where c-erbB-2 is expressed
(Quirke et al., 1989).
Our findings suggest that the putative ligand of c-erbB-2 is
secreted into parenchymal organs in which the c-erbB-2 pro-
tein is expressed. The fact, that c-erbB-2 positive tumours
show the tendency to select one parenchymal organ for
metastising requires further investigation.
In conclusion our results show that c-erbB-2 positive
tumours spread earlier. Most of the metastases are seen in
the first three years after diagnosis. As a result of early
metastases these patients have a shorter OST.
Our study is the first to provide us with an explanation for
the discrepancies in literature between c-erbB-2 expression
and different prognoses. Groups of authors who looked for a
bad prognosis in the first years after diagnosis were able to
show a difference in prognosis (Slamon et al., 1987; Varley et
al., 1987; Gusterson et al., 1988; Thor et al., 1989; Tsuda et
al., 1989; Wright et al., 1989a; De Potter et al., 1990). Some
authors who carried out investigations in a long follow-up
period of more than 5 to 10 years did not find a difference in
prognosis between c-erbB-2 positive and negative patients
(Gusterson et al., 1988; van de Vivjer et al., 1988; Barnes et
al., 1988), other authors (Lovekin et al., 1991; Wistanley et
al., 1991) found a difference in prognoses in a long follow-up
period of more than 5 years between c-erbB-2 positive and
negative patients. Our study only showed differences within a
short follow-up period of up to 3 years in DFS and up to 4
years in OST and between c-erbB-2 positive and negative
tumours. These differences vanish in a longer follow-up
period up to 12 years.
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